This research improves preclinical testing of SERDs (selective estrogen receptor degraders) for estrogen receptor–positive breast cancer by modeling the tumor environment and treatment resistance. By co-culturing cancer and fat cells and applying single-cell RNA sequencing, it identifies resistance mechanisms to support more effective drug development for patients.